Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Effects Of Chromium Supplementation On Serum High-density Lipoprotein Cholesterol Levels In Men Taking Beta-blockers. A Randomized, Controlled Trial.

J. R. Roeback, K. M. Hla, L. Chambless, R. Fletcher
Published 1991 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To determine the efficacy of glucose tolerance factor (GTF)-chromium for increasing serum levels of high-density lipoprotein (HDL) cholesterol in patients taking beta-blockers. DESIGN Randomized, double-blind, placebo-controlled trial. SETTING Mixed primary and referral-based outpatient clinic at a university-affiliated VA Medical Center. PATIENTS Referred sample of 72 men receiving beta-blockers, mainly for hypertension. Sixty-three patients (88%) completed the study. INTERVENTIONS Current medications, including beta-blockers, were continued. During the 8-week treatment phase, patients in the chromium group received a total daily dose of 600 micrograms of biologically active chromium divided into three equal doses; control patients received a placebo of identical appearance and taste. MEASUREMENTS Serum levels of total cholesterol and HDL cholesterol were measured. MAIN RESULTS Mean baseline levels of HDL and total cholesterol (+/- SD) were 0.93 +/- 0.28 mmol/L and 6.0 +/- 1.0 mmol/L (36 +/- 11.1 mg/dL and 232 +/- 38.5 mg/dL), respectively. The difference between groups in adjusted mean change in HDL cholesterol levels, accounting for baseline HDL cholesterol levels, age, weight change, and baseline total cholesterol levels, was 0.15 mmol/L (5.8 mg/dL) (P = 0.01) with a 95% Cl showing that the treatment effect was greater than +0.04 mmol/L (+1.4 mg/dL). Mean total cholesterol, triglycerides and body weight did not change significantly during treatment for either group. Compliance as measured by pill count was 85%, and few side effects were reported. Two months after the end of treatment, the between-group difference in adjusted mean change from baseline to end of post-treatment follow-up was -0.003 mmol/L (-0.1 mg/dL). CONCLUSION Two months of chromium supplementation resulted in a clinically useful increase in HDL cholesterol levels in men taking beta-blockers.
This paper references
10.1093/EURHEARTJ/11.SUPPL_H.21
Serum lipoproteins as risk factors: recent epidemiologic studies in individuals with and without prevalent cardiovascular disease.
H. Tyroler (1990)
10.1093/CLINCHEM/28.6.1379
Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.
G. Warnick (1982)
10.1152/PHYSREV.1969.49.2.163
Chromium occurrence and function in biological systems.
W. Mertz (1969)
10.2307/2531561
The design and analysis of clinical experiments
J. Fleiss (1986)
10.1080/07315724.1982.10718995
Effect of high-chromium brewer's yeast on human serum lipids.
J. Elwood (1982)
10.1016/0002-9149(90)90017-U
Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease.
M. Miller (1990)
10.1016/0026-0495(83)90203-2
Chromium supplementation of human subjects: effects on glucose, insulin, and lipid variables.
R. Anderson (1983)
10.1161/01.CIR.79.1.8
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
D. Gordon (1989)
10.1016/0026-0495(87)90206-X
Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia.
R. Anderson (1987)
10.1093/AJCN/34.12.2670
Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men.
R. Riales (1981)
10.1016/0002-9343(87)90137-9
Antihypertensive drugs: how different classes can impact patients' coronary heart disease risk profile and quality of life.
N. Kaplan (1987)
10.1021/JF60223A036
Determination of chromium in selected United States diets.
J. Kumpulainen (1979)
10.1001/JAMA.1988.03410050061031
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
V. Manninen (1988)
10.1016/0033-0620(86)90038-1
The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials.
S. Macmahon (1986)
10.1161/01.ATV.8.3.207
High Density Lipoprotein Cholesterol, Total Cholesterol Screening, and Myocardial Infarction: The Framingham Study
R. Abbott (1988)
10.1080/07315724.1985.10720070
Clinical and biochemical aspects of chromium deficiency.
S. Wallach (1985)
10.1007/978-3-642-74117-3_3
Mechanistic aspects of chromium carcinogenicity.
S. De Flora (1989)
The effects of diuretics and adrenergic-blocking agents on plasma lipids.
Rohlfing Jj (1986)
10.1016/0021-9150(83)90196-X
Coronary heart disease in 'low risk' men.
R. Heller (1983)
10.1016/0002-9343(87)90205-1
Calcium and vascular smooth muscle tone.
K. Morgan (1987)
Effects of chromium III on fasting blood glucose, cholesterol and cholesterol HDL levels in diabetics.
Mossop Rt (1983)
10.2105/AJPH.79.3.340
Modeling and variable selection in epidemiologic analysis.
S. Greenland (1989)
10.1016/0026-0495(86)90007-7
Effects of diets high in simple sugars on urinary chromium losses.
A. Kozlovsky (1986)
10.1093/AJCN/41.6.1177
Chromium intake, absorption and excretion of subjects consuming self-selected diets.
R. Anderson (1985)
10.1093/AJCN/39.5.797
The uptake and excretion of chromium by the elderly.
V. Bunker (1984)
10.1002/SIM.4780070903
Methods for assessing whether change depends on initial value.
R. Hayes (1988)
THE EFFECT OF A HIGH CHROMIUM YEAST ON THE BLOOD GLUCOSE CONTROL AND BLOOD LIPIDS OF NORMAL AND DIABETIC HUMAN SUBJECTS
P. Bose (1984)
10.1016/0002-9343(89)90120-4
Effects of antihypertensive agents on serum lipids and lipoproteins.
A. Chait (1989)
10.1111/J.1753-4887.1975.TB07105.X
Effects and metabolism of glucose tolerance factor.
W. Mertz (1975)
10.1016/0140-6736(90)90878-9
Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias
S. Macmahon (1990)
10.1093/AJCN/30.4.531
Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition.
K. Jeejeebhoy (1977)



This paper is referenced by
10.1016/J.TET.2012.01.047
Benzimidazole-based imine-linked chemosensor: chromogenic sensor for Mg2+ and fluorescent sensor for Cr3+
Preeti Saluja (2012)
10.2165/00007256-199723060-00001
Effects of Exercise on Chromium Levels
P. Clarkson (1997)
10.1016/j.cjca.2010.12.077
The impact of dietary changes and dietary supplements on lipid profile.
J. Huang (2011)
10.2337/diab.46.11.1786
Elevated Intakes of Supplemental Chromium Improve Glucose and Insulin Variables in Individuals With Type 2 Diabetes
R. Anderson (1997)
10.1046/J.1525-1446.2001.00436.X
The influence of the hypertensive patient's education in compliance with their medication.
M. Saounatsou (2001)
10.1111/obr.12026
Chromium supplementation in overweight and obesity: a systematic review and meta‐analysis of randomized clinical trials
I. Onakpoya (2013)
10.1097/00005768-199708000-00003
Chromium and exercise training: effect on obese women.
K. E. Grant (1997)
10.1093/AJCN/73.1.99
Serum chromium does not predict glucose tolerance in late pregnancy.
J. Gunton (2001)
10.1016/0895-4356(93)90115-H
Time-dependent variability in repeated measurements of cholesterol levels: clinical implications for risk misclassification and intervention monitoring.
J. R. Roeback (1993)
10.1089/ACM.2006.6206
Dietary supplements for the prevention and treatment of coronary artery disease.
Jeffrey V. Knox (2007)
10.1016/S0985-0562(00)80002-3
Apports nutritionnels conseillés chez la personne âgée
L. Cynober (2000)
10.1016/S0277-5387(00)00624-0
The bioinorganic chemistry of chromium(III)
J. Vincent (2001)
10.2337/DIACARE.27.11.2741
Role of Chromium in Human Health and in Diabetes
W. Cefalu (2004)
10.1016/0306-9877(93)90073-Y
Homologous physiological effects of phenformin and chromium picolinate.
M. Mccarty (1993)
10.1016/j.jnutbio.2008.02.010
Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells.
Pilaiwan Siripurkpong (2009)
10.2337/DC13-ER09
Role of chromium in human health and in diabetes. Diabetes Care 2004;27:2741–2751
W. Cefalu (2013)
10.1016/J.CCT.2004.06.001
Adjustment for baseline measurement error in randomized controlled trials induces bias.
S. Chan (2004)
10.1080/01480540600820429
The Effect of Combined Treatment with Niacin and Chromium (III) Chloride on the Different Tissues of Hyperlipemic Rats
I. A. Atac (2006)
10.1590/S0080-62341998000400007
A adesão ao tratamento na hipertensão arterial: análise da produção científica
L. M. Sarquis (1998)
A Sound Nutritional Approach to Creating & Maintaining Constant Health
Cindy Marteney (2008)
10.3949/CCJM.70.6.553
Raising an isolated low HDL-C level: why, how, and when?
M. Miller (2003)
Chromium in the prevention and control of diabetes.
R. Anderson (2000)
10.1016/B978-0-12-416595-3.00003-7
Environmental Toxins and the Heart
S. Rahnama-Moghadam (2014)
Nutritional Support for Insulin Resistance : A Summary
Dan Lukaczer (2003)
10.1201/9781420019322.CH11
Chromium: Roles in the Regulation of Lean Body Mass and Body Weight
R. Anderson (2006)
10.1152/PHYSIOLGENOMICS.00071.2006
Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium.
Cameron Rink (2006)
10.1080/10408690091189167
Chromium, Exercise, and Body Composition
H. V. Kobla (2000)
10.1080/07315724.1998.10718802
Chromium, glucose intolerance and diabetes.
R. Anderson (1998)
10.1016/S0033-0620(98)80010-8
Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol.
L. Belalcazar (1998)
10.1016/S0306-9877(97)90219-X
Exploiting complementary therapeutic strategies for the treatment of type II diabetes and prevention of its complications.
M. Mccarty (1997)
10.1093/AJCN/63.6.954
Chromium supplementation and resistance training: effects on body composition, strength, and trace element status of men.
H. Lukaski (1996)
10.1002/JTRA.10053
Can Long-Term Exposure to Chromium Improve Insulin Sensitivity in Chromium Mine Workers?
A. Tuzcu (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar